An inhibitory monoclonal antibody to human cytochrome P450 that specifically binds and inhibits P4502C9II, an allelic variant of P4502C9 having a single amino acid change Arg144 Cys

Xenobiotica

Volumn 30, Issue 6, 2000, Pages 619-625

  Krausz, K W ^a   Goldfarb, I ^a   Yang, T J ^a   Gonzalez, F J ^a   Gelboin, H V ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; DICLOFENAC; MONOCLONAL ANTIBODY; PHENANTHRENE; TOLBUTAMIDE;

ANIMAL CELL; ARTICLE; CATALYSIS; ENZYME ANALYSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; INHIBITION KINETICS; MOUSE; NONHUMAN; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN STRUCTURE; XENOBIOTIC METABOLISM;

EID: 0033922921     PISSN: 00498254     EISSN: None     Source Type: Journal    
DOI: 10.1080/004982500406444     Document Type: Article

References (31)

1. BATTULA, N., SAGARA, J. and GELBOIN, H. V., 1987, Expression of P1-450 and P3-450 DNA coding sequences as enzymatically active cytochromes P-450 in mammalian cells. Proceedings of the National Academy of Sciences, USA, 12, 4073-4077.
2. CRESPI, C. L. AND PENMAN, B. W., 1997, Use of cDNA-expressed human cytochrome P450 enzymes to study potential drug-drug interactions. Advances in Pharmacology, 43, 171-188.
3. FUJINO, T., PARK, S. S., WEST, D. and GELBOIN, H. V., 1982, Phenotyping of cytochromes P-450 in human tissues with monoclonal antibodies. Proceedings of the National Academy of Sciences, USA, 79, 3682-3686.
4. GELBOIN, H. V., 1993, Monoclonal antibodies and cytochrome P450. Pharmacological Reviews, 45, 413-453.
5. GELBOIN, H. V., GOLDFARH, I., KRAUSZ, K. W., GROGAN, J., KORZEKWA, K. R., GONZALEZ, F. J. and SHOU, M., 1996, Inhibitory and non-inhibitory monoclonal antibodies to human cytochrome P450 2EI. Chemical Research Toxicology, 9, 1023-1030.
6. GELBOIN, H. V., KRAUSZ, K. W., GOLDFARB, I., BUTERS, J. T. M., YANG, S. K., GONZALEZ, F. J., KORZEKWA, K. R. and SHOU, M., 1995, Inhibitory and non inhibitory monoclonal antibodies to human cytochrome P450 3A3/4. Biochemical Pharmacology, 50, 1841-1850.
7. GELBOIN, H. V., KRAUSZ, K. W., GONZALEZ, F. J. and YANG, T. J., 1999, Monoclonal antibodies and human cytochromes P450: a new avenue for drug discovery. Trends in Pharmacological Science, 20, 432-438.
8. GELBOIN, H. V., KRAUSZ, K. W., SHOU, M., GONZALEZ, F. J. and YANG, T. J., 1997, A monoclonal antibody inhibitory to human P450 2D6: a paradigm for use in combinatorial determination of individual P450 role in specific drug tissue metabolism. Pharmacogenetics, 7, 469-477.
9. GELBOIN, H. V., SHOU, M., GOLDFARB, I., YANG, T. J. and KRAUSZ, K. W., 1998, Monoclonal antibodies to cytochrome P450. In I. R. Phillips and E. A. Shephard (eds), Methods in Molecular Biology: Cytochrome P450 Protocols (New Jersey: Humana), pp. 227-237.
10. GONZALEZ, F. J., KIMURA, S., TAMURA, S. and GELBOIN, H. V., 1991, Expression of mammalian cytochrome P 450 using baculovirus. Methods in Enzymology, 206, 93-99.
11. HAINING, R. L., HUNTER, A. P., VERONESE, M. E., TRAGER, W. F. and RETTIE, A. E., 1996, Allelic variants of human cytochrome P450 2C9: baculovirus-mediated expression, purification, structural characterization, substrate stereoselectivity, and prochiral selectivity of the wild-type and I359L mutant forms. Archives of Biochemistry and Biophysics, 333, 447-458.
12. INGELMAN-SUNDBERG, M., OSCARSON, M. and MCLELLAN, R. A., 1999, Polymorphic human cytochrome P450 enzymes: an opportunity for individualized drug treatment. Trends in Pharmacological Sciences, 20, 342-349.
13. IOANNIDES, C. (ed.), 1996, Cytochrome P450: Metabolic and Toxicology Aspects (Boca Raton: CRC Press), pp. 1-411.
14. KOHLER, G. and MILSTEIN, C., 1975, Continuous cultures of fused cells secreting antibody of predefined specificity. Nature, 7, 495-497.
15. MINERS, J. O. and BIRKETT, D. J. 1998, Cytochrome P 450 2C9: an enzyme of major importance in human drug metabolism. British Journal of Clinical Pharmacology, 45, 525-538.
16. MONTELLANO, O. (ed.), 1995, Cytochrome P 450: Structure, Mechanism and Biochemistry (London: Plenum), pp. 473-535.
17. NASU, K., KUBOTA, T. and ISHIZAKI, T., 1997, Genetic analysis of CYP2C9 polymorphism in a Japanese population. Pharmacogenetics, 7, 405-409.
18. RELLING, M. V., AOYAMA, T., GONZALEZ, F. J. and MEYER, U. A., 1990, Tolbutamide and mephenytoin hydroxylation by human cytochrome P450s in the CYP2C subfamily. American Society for Pharmacology and Experimental Therapeutics, 252, 442-447.
19. RENDIC, S. and DI CARLO, F. J., 1997, Human cytochrome P450 enzymes: status report summarizing their reactions, substrates, inducers, and inhibitors. Drug Metabolism Reviews, 29, 413-580.
20. RETTIE, A. E., WIENKERS, L. C., GONZALEZ, F. J., TRAGER, W. F. and KORZEKWA, K. R., 1994, Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9. Pharmacogenetics, 4, 39-42.
21. SAI, Y., YANG, T. J., KRAUSZ, K. W., GONZALEZ, F. J. and GELBOIN, H. V., 1999, An inhibitory monoclonal antibody to human cytochrome P450 2A6 defines its role in the metabolism of coumarin, 7-ethoxycoumarin and 4-nitroanisole in human liver. Pharmacogenetics, 9, 229-237.
22. SHOU, M., KORZEKWA, K. R., KRAUSZ, K. W., CRESPI, C. L., GONZALEZ, F. J. and GELBOIN, H. V., 1994, Regio- and stereo-selective metabolism of phenanthrene by twelve cDNA expressed human, rodent, and rabbit cytochromes P-450. Cancer Letters, 83, 305-313.
23. STUBBINS, M. J., HARRIES, L. W., SMITH, G., TARBIT, M. H. and WOLF, C. R., 1996, Genetic analysis of the human cytochrome P450 CYP2C9 locus. Pharmacogenetics, 6, 429-439.
24. SULLIVAN-KLOSE, T. H., GHANAYEM, B. I., BELL, D. A., ZHANG, Z. Y., KAMINSKY, L. S., SHENFIELD, G. M., MINERS, J. O., BIRKETT, D. J. and GOLDSTEIN, J. A., 1996, The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics, 6, 341-349.
25. TASSANEEYAKUL, W., BERKETT, D. J., VERONESE, M. E., MCMANUS, M. E., TUKEY, R. H., QUATTROCHI, L. C., GELBOIN, H. V. and MINERS, J. O., 1993, Specificity of substrate and inhibitor probes for human cytochromes P 450 1A1 and 1A2. Journal of Pharmacology Experimental Therapy, 1, 401-407.
26. VERONESE, M. E., MACKENZIE, P. I., DOECKE, D. J., MCMANUS, M. E., MINORS, J. O. and BIRKETT, D. J., 1991, Tolbutamide and phenytoin hydroxylations by cDNA-expressed human liver cytochrome P450 2C9. Biochemical Biophysical Research Communications, 175, 1112-1118.
27. YAMAZAKI, H., INOUE, K., CHIBA, K., OZAWA, N., KAWAI, T., SUZUKI, Y., GOLDSTEIN, J. A., GUENGERICH, F. P. and SHIMADA, T., 1998, Comparative studies on the catalytic roles of cytochrome P450 2C9 and its Cys- and Leu-variants in the oxidation of warfarin, flurbiprofen, and diclofenac by human liver microsomes. Biochemical Pharmacology, 56, 243-251.
28. YANG, T. J., KRAUSZ, K. W., SHOU, M., YANG, S. K., BUTERS, J. T. M., GONZALEZ, F. J. and GELBOIN, H. V., 1998a, Inhibitory monoclonal antibody to human cytochrome P450 2B6. Biochemical Pharmacology, 55, 1633-1640.
29. YANG, T. J., KRAUSZ, K. W., SAI, Y., GONZALEZ, F. J. and GELBOIN, H. V., 1999, Eight inhibitory monoclonal antibodies define the role of individual P450s in human liver microsomal diazepam, 7-ethoxycoumarin and imipramine metabolism. Drug Metabolism and Disposition, 27, 102-109.
30. YANG, T. J., SAI, Y., KRAUSZ, K. W., GONZALEZ, F. J. and GELBOIN, H. V., 1998b, Inhibitory Monoclonal Antibodies to Human cytochrome P450 1A2: analysis of phenacetin o-deethylation in human liver. Pharmacogenetics, 8, 375-382.
31. YASAR, U., ELIASSON, E., DAHL, M. L., JOHANSSON, I., INGELMAN-SUNDBERG, M. and SJOQVIST, F., 1999, Validation of methods for CYP2C9 genotyping: frequencies of mutant alleles in a Swedish population. Biochemical and Biophysical Research Communications, 254, 628-631.